CFO Vanessa Kanu reported Q4 adjusted EBITDA of $195 million, representing a 9% increase year-over-year. She attributed the 27% increase in adjusted diluted EPS to strong margins and a lower tax rate ...
However, we still see areas of weakness in the portfolio, including upcoming patent losses and a highly uncertain pipeline due to the complexities of running CNS trials. Historically, the firm ...